Overview

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Hormone therapy may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to evaluate the effectiveness of treatment with flutamide and suramin with or without hydrocortisone in men who have metastatic or recurrent prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Eastern Cooperative Oncology Group
Collaborators:
Cancer and Leukemia Group B
National Cancer Institute (NCI)
Southwest Oncology Group
Treatments:
Cortisol succinate
Flutamide
Goserelin
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Leuprolide
Suramin